Loading...
•
Sep 30, 2024
Heron Therapeutics Q3 2024 Earnings Report
Heron Therapeutics reported positive Adjusted EBITDA and revenue growth.
Key Takeaways
Heron Therapeutics announced its Q3 2024 financial results, reporting positive Adjusted EBITDA and continued revenue growth. The company is narrowing its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA. Key developments include the approval and upcoming launch of the ZYNRELEF VAN and the inclusion of ZYNRELEF in the CMS Final Rule Non-Opioid Policy for Pain Relief.
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million.
Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million.
ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle (“VAN”) approved in September and on track for Q4 2024 launch.
CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
The Company narrows its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA.
Revenue & Expenses
Visualization of income flow from segment revenue to net income